Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
147.8 USD | +3.11% | +1.15% | -22.96% |
08/04 | Sector Update: Health Care Stocks Flat to Higher Premarket Monday | MT |
08/04 | Sector Update: Health Care | MT |
Business Summary
Number of employees: 2,100
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Ribonucleic Acid Interference Therapeutics
100.0
%
| 1,037 | 100.0 % | 1,828 | 100.0 % | +76.23% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
69.8
%
| 616 | 59.4 % | 1,276 | 69.8 % | +107.21% |
Europe
21.8
%
| 315 | 30.4 % | 399 | 21.8 % | +26.83% |
Rest of the World
8.4
%
| 107 | 10.3 % | 153 | 8.4 % | +43.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 19/16/19 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 13/19/13 |
Piyush Sharma
CMP | Compliance Officer | - | 21/22/21 |
Chief Tech/Sci/R&D Officer | - | 01/17/01 | |
Kevin Fitzgerald
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/05/01 |
James Bilotta
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Pushkal Garg
CTO | Chief Tech/Sci/R&D Officer | 56 | 29/14/29 |
Joshua Brodsky
IRO | Public Communications Contact | - | 01/21/01 |
Investor Relations Contact | 43 | 01/15/01 | |
Eric Green
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 18/15/18 |
Charles Sigal
BRD | Director/Board Member | 72 | 22/22/22 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 10/19/10 |
Amy Schulman
CHM | Chairman | 63 | 01/14/01 |
Phillip Sharp
FOU | Founder | 79 | 14/02/14 |
Peter Kellogg
BRD | Director/Board Member | 67 | 07/23/07 |
Michael Bonney
BRD | Director/Board Member | 65 | 17/14/17 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 23/12/23 |
Colleen Reitan
BRD | Director/Board Member | 64 | 01/18/01 |
Chief Executive Officer | 61 | 19/16/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 125,933,946 | 125,412,321 ( 99.59 %) | 0 | 99.59 % |
Company contact information
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street Henri A. Termeer Square
02142, Cambridge
+617 551 8200
http://www.alnylam.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.96% | 18.12B | |
+2.45% | 42.75B | |
+47.70% | 41.61B | |
+12.14% | 41.34B | |
-12.36% | 26.59B | |
+8.83% | 25.49B | |
+30.87% | 12.24B | |
-1.44% | 11.76B | |
+8.49% | 11B | |
-14.27% | 10.07B |
- Stock Market
- Equities
- ALNY Stock
- Company Alnylam Pharmaceuticals, Inc.